Establishment and verification of microscopy review rules in AVE automatic urine analysis

doi:10.3969/j.issn.1673-8640.2017.01.006

Abstract

Abstract:

Objective To establish microscopy review rules of AVE automatic urine analysis. Methods Urine dry chemical and urinary sediment analysis was performed for 2 278 urine samples by AVE-752 urine dry chemical analyzer and AVE-766 urinary sediment analyzer. All samples were screened by microscopy with double blind method. AVE-752 and AVE-766 results,modified results and microscopy results were all recorded. Taking the average of microscopy results as standard,the review rules and review rates were established by false negative rates,false positive rates and error rates of 4 schemes（scheme 1：the results of AVE-752 and AVE-766 were analyzed directly;scheme 2：the modified results of AVE-752 and AVE-766 were analyzed;scheme 3：the positive results of scheme 1 were reviewed by microscopy and analyzed; scheme 4：the positive results of scheme 2 were reviewed by microscopy and analyzed）,which were based on leucocyte esterase （LEU）,occult blood （BLD） and protein （Pro）by AVE-752 and white blood cell（WBC）, red blood cell（RBC） and cast（Cast） by AVE-766 and/or modified. A total of 344 urine samples were determined to verify review rules. Results The false positive rates were 20.4%,13.5%,0.0% and 0.0%,the false negative rates were 8.9%,4.2%,8.9% and 4.2%,and the error rates were 16.8%,10.6%,2.8% and 1.3% . The review rates of scheme 3 and scheme 4 were 42.4% and 39.1%,108 samples with false positive results were modified （76 cases of WBC,23 cases of RBC and 9 cases of Cast）,and 33 samples with false negative results were modified（8 cases of WBC and 25 cases of RBC）. There still existed 30 samples with false negative results （12 cases of WBC and 18 cases of RBC）after modification. The false positive rate of 344 verified urine samples was 0.0%,the false negative rate was 4.5%,the error rate was 1.5%,and the review rate was 35.2%. Conclusions After the combined usage of AVE-752 and AVE-766,all samples should be screened by microscopy except LEU/WBC,BLD/RBC and Pro/Cast.

Key words: Urine routine analysis, Review rule, Review rate

CLC Number:

R446.1

LIU Wanchao, CHEN Longmei, YANG Zhenhua, LI Dong. Establishment and verification of microscopy review rules in AVE automatic urine analysis[J]. Laboratory Medicine, 2017, 32(1): 22-25.

Figures/Tables 3

References 10

1	尚红,王毓三,申子瑜. 全国临床检验操作规程[M]. 4版. 北京:人民卫生出版社,2015:160-174.
2	刘成玉,罗春丽. 临床检验基础[M]. 5版. 北京:人民卫生出版社,2014:167.
3	陈雨,程闽,李薇,等. 自动化尿液干化学和有形成分分析复检规则的制定和应用[J]. 中华检验医学杂志,2011,34(6):501-506.
4	BARNES P W,MCFADDEN S L, MACHIN S J, et a1. The international consensus group for hematology review:suggested criteria for action following automated CBC and WBC differential analysis[J]. Lab Hematol,2005,11(2):83-90.
5	马骏龙,丛玉隆,陆玉静,等. 尿干化学与流式细胞术联合用于尿液有形成分镜检筛选的研究与应用[J]. 中华检验医学杂志, 2011,34(6):494-500.
6	黄玉霞,黄珣钡,邓山鹰,等. 尿液分析系统复检规则的建立及流程优化[J]. 临床检验杂志, 2012,30(8):567-569.
7	赵莹,丁生乐. AVE-764B尿液有形成分分析仪检测尿有形成分的性能评价[J]. 国际检验医学杂志,2014,36(24):3418-3419.
8	刘其爱. AVE-764B尿液有形成分分析仪的临床应用评价[J]. 国际检验医学杂志,2014,36(155):2075-2076.
9	张志英,戴燕,李冬,等. AVE-766尿液有形成分分析仪的性能评价及临床应用价值[J]. 临床检验杂志(电子版),2014,3(3):678-682.
10	吕纯莉,肖代敏,朱绍玲,等. URIT-1500尿干化学分析仪与AVE-764B尿有形成分分析仪联合尿液检测复检规则的制定和应用[J]. 检验医学,2016,31(1):45-48.

参数	结果	AVE-752	AVE-766 （个/μL）	显微镜镜检（个/μL）
参数	结果	AVE-752	AVE-766 （个/μL）	男	女
LEU/WBC	-	-	0~12	0~5	0~12
	+	+、2+、3+	>12	>5	>12
BLD/RBC	-	-	0~10	0~4	0~9
	+	±、+、2+、3+	>10	>4	>9
Pro/Cast	-	-	0~2	透明Cast 0~偶见
	+	±、+、2+、3+、4+	>2	>1

参数	结果	AVE-752	AVE-766 （个/μL）	显微镜镜检（个/μL）
参数	结果	AVE-752	AVE-766 （个/μL）	男	女
LEU/WBC	-	-	0~12	0~5	0~12
	+	+、2+、3+	>12	>5	>12
BLD/RBC	-	-	0~10	0~4	0~9
	+	±、+、2+、3+	>10	>4	>9
Pro/Cast	-	-	0~2	透明Cast 0~偶见
	+	±、+、2+、3+、4+	>2	>1

方案	假阳性率	假阴性率	错误率	复检率
1	20.4（320/1 570）	8.9（63/708）	16.8（383/2 278）	0.0（0/2 278）
2	13.5（212/1 570）	4.2（30/708）	10.6（242/2 278）	0.0（0/2 278）
3	0.0（0/1 570）	8.9（63/708）	2.8（63/2 278）	42.4（965/2 278）
4	0.0（0/1 570）	4.2（30/708）	1.3（30/2 278）	39.1（890/2 278）

方案	假阳性率	假阴性率	错误率	复检率
1	20.4（320/1 570）	8.9（63/708）	16.8（383/2 278）	0.0（0/2 278）
2	13.5（212/1 570）	4.2（30/708）	10.6（242/2 278）	0.0（0/2 278）
3	0.0（0/1 570）	8.9（63/708）	2.8（63/2 278）	42.4（965/2 278）
4	0.0（0/1 570）	4.2（30/708）	1.3（30/2 278）	39.1（890/2 278）

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.